Visual Cortex in Dogs and Humans with RPE65 Mutation
Author Information
Author(s): Aguirre Geoffrey K, Komáromy András M, Cideciyan Artur V, Brainard David H, Aleman Tomas S, Roman Alejandro J, Avants Brian B, Gee James C, Korczykowski Marc, Hauswirth William W, Acland Gregory M, Aguirre Gustavo D
Primary Institution: University of Pennsylvania
Hypothesis
How does the visual cortex respond after prolonged sensory deprivation from retinal dysfunction in RPE65-mutant dogs and humans?
Conclusion
Retinal gene therapy significantly improves visual cortical responses in dogs, and humans with RPE65 mutations retain some visual pathway integrity despite limited visual experience.
Supporting Evidence
- Gene therapy restored retinal and subcortical responses to light in RPE65-mutant dogs.
- Visual cortical responses improved significantly after gene therapy in treated dogs.
- Human RPE65-LCA patients showed preserved visual pathway anatomy despite severe visual loss.
- Functional MRI revealed cortical activation in humans with RPE65 mutations when stimulated with bright light.
Takeaway
This study shows that even if someone has been blind for a long time, their brain can still learn to see again if we fix their eyes.
Methodology
The study used fMRI to measure visual responses in RPE65-mutant dogs before and after gene therapy, and compared these results with human patients with RPE65-LCA.
Potential Biases
Potential bias in participant selection and the small sample size may affect the reliability of the findings.
Limitations
The study's sample size was small, and results may not generalize to all individuals with RPE65 mutations.
Participant Demographics
Six RPE65-LCA patients aged 18-23 years and eight control individuals aged 20-42 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website